2026 Q2 - tulosraportti
84 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 337 | ||
| 135 | ||
| 134 | ||
| 269 | ||
| 537 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sittenEli Lilly beats Novo Nordisk in head-to-head trial 💊 Significantly better weight loss. Lilly's retatrutide delivered 19.5–20.9% weight loss vs 9.4% for Ozempic 2 mg in patients with type 2 diabetes. Better blood sugar control. HbA1c fell 2.2 percentage points vs 1.8 for Ozempic. Also improvements in several cardiovascular risk factors. Side effects are a challenge and several patients stopped treatment with retatrutide due to side effects (up to 7.9% vs 2.7%). Novo comes under further pressure as the results strengthen Lilly's position within next-generation obesity and diabetes treatments. However, retatrutide remains an investigational drug. In my view, this is yet another strong clinical result for Lilly and a clear competitive warning signal to Novo Nordisk. But the comparison is with Ozempic 2 mg and not Novo's highest Wegovy dose or upcoming pipeline products. Therefore, the results alone cannot determine future competition. For Novo, the pipeline, differentiation and ability to defend market share are becoming increasingly important. Lilly is clearly raising the bar. Source: Clinical Trials Arena, 28 October 2026.
It will be interesting when the report comes out whether Novo still makes as much money since they are forced to constantly lower their prices and thus their margins. If the report shows that they can still have a good margin, I believe it could be a small boost.
·3 t sittenGenmab/Novo. Genmab shows that a stock can go from total depth of despair to higher altitudes when the market suddenly gains confidence in the company's pipeline. The stock has risen massively after strong trial results. The question is then whether Novo can do the same. They certainly can, but it requires Novo to once again deliver strong results with new obesity and diabetes drugs, win some market share from Eli Lilly and get investors to believe in growth again. Therefore, Novo can easily make a strong comeback, but you should not necessarily expect the same explosive percentage increases as in Genmab. Not a buy/sell recommendation.
Agree with what you are writing. For a long time, the Genmab share reacted exactly the way Novo does today - it fell on both good and bad news. Patience rewards itself and trust can quickly be regained. Pleased with Genmab's success and believe it will soon turn around for Novo too.
·4 t sittenMy thoughts. I believe in a positive report and a positive market reaction next week. At the last report we were approx 80 kr higher around 330-335. So it has already taken a beating. Dollar is strengthening, which is good for Novo and they are rapidly entering new markets. Last time, I had sold off nicely before the report. This time I have loaded up. 🆙
Before the last earnings report, the share price was around 305. Inconceivable how little factual information there is here. Everything is drifting.- ·4 t sittenGenmab on the way to overtake novo in market value? It is approaching well 3-400 billion kr? Fantastic news today for the people who are diagnosed with head and neck cancer. Simply fantastic !!!!!Novo on the other hand is about to get an obesity product approved in Dubai. The market is excited and responds with a minor drop of a couple of percent. Novo is doing eminently.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 5 015 221 | 5 015 221 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 5 015 221 | 5 015 221 | 0 | 0 |
2026 Q2 - tulosraportti
84 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenEli Lilly beats Novo Nordisk in head-to-head trial 💊 Significantly better weight loss. Lilly's retatrutide delivered 19.5–20.9% weight loss vs 9.4% for Ozempic 2 mg in patients with type 2 diabetes. Better blood sugar control. HbA1c fell 2.2 percentage points vs 1.8 for Ozempic. Also improvements in several cardiovascular risk factors. Side effects are a challenge and several patients stopped treatment with retatrutide due to side effects (up to 7.9% vs 2.7%). Novo comes under further pressure as the results strengthen Lilly's position within next-generation obesity and diabetes treatments. However, retatrutide remains an investigational drug. In my view, this is yet another strong clinical result for Lilly and a clear competitive warning signal to Novo Nordisk. But the comparison is with Ozempic 2 mg and not Novo's highest Wegovy dose or upcoming pipeline products. Therefore, the results alone cannot determine future competition. For Novo, the pipeline, differentiation and ability to defend market share are becoming increasingly important. Lilly is clearly raising the bar. Source: Clinical Trials Arena, 28 October 2026.It will be interesting when the report comes out whether Novo still makes as much money since they are forced to constantly lower their prices and thus their margins. If the report shows that they can still have a good margin, I believe it could be a small boost.
- ·3 t sittenGenmab/Novo. Genmab shows that a stock can go from total depth of despair to higher altitudes when the market suddenly gains confidence in the company's pipeline. The stock has risen massively after strong trial results. The question is then whether Novo can do the same. They certainly can, but it requires Novo to once again deliver strong results with new obesity and diabetes drugs, win some market share from Eli Lilly and get investors to believe in growth again. Therefore, Novo can easily make a strong comeback, but you should not necessarily expect the same explosive percentage increases as in Genmab. Not a buy/sell recommendation.Agree with what you are writing. For a long time, the Genmab share reacted exactly the way Novo does today - it fell on both good and bad news. Patience rewards itself and trust can quickly be regained. Pleased with Genmab's success and believe it will soon turn around for Novo too.
- ·4 t sittenMy thoughts. I believe in a positive report and a positive market reaction next week. At the last report we were approx 80 kr higher around 330-335. So it has already taken a beating. Dollar is strengthening, which is good for Novo and they are rapidly entering new markets. Last time, I had sold off nicely before the report. This time I have loaded up. 🆙Before the last earnings report, the share price was around 305. Inconceivable how little factual information there is here. Everything is drifting.
- ·4 t sittenGenmab on the way to overtake novo in market value? It is approaching well 3-400 billion kr? Fantastic news today for the people who are diagnosed with head and neck cancer. Simply fantastic !!!!!Novo on the other hand is about to get an obesity product approved in Dubai. The market is excited and responds with a minor drop of a couple of percent. Novo is doing eminently.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 337 | ||
| 135 | ||
| 134 | ||
| 269 | ||
| 537 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 5 015 221 | 5 015 221 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 5 015 221 | 5 015 221 | 0 | 0 |
2026 Q2 - tulosraportti
84 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,49%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sittenEli Lilly beats Novo Nordisk in head-to-head trial 💊 Significantly better weight loss. Lilly's retatrutide delivered 19.5–20.9% weight loss vs 9.4% for Ozempic 2 mg in patients with type 2 diabetes. Better blood sugar control. HbA1c fell 2.2 percentage points vs 1.8 for Ozempic. Also improvements in several cardiovascular risk factors. Side effects are a challenge and several patients stopped treatment with retatrutide due to side effects (up to 7.9% vs 2.7%). Novo comes under further pressure as the results strengthen Lilly's position within next-generation obesity and diabetes treatments. However, retatrutide remains an investigational drug. In my view, this is yet another strong clinical result for Lilly and a clear competitive warning signal to Novo Nordisk. But the comparison is with Ozempic 2 mg and not Novo's highest Wegovy dose or upcoming pipeline products. Therefore, the results alone cannot determine future competition. For Novo, the pipeline, differentiation and ability to defend market share are becoming increasingly important. Lilly is clearly raising the bar. Source: Clinical Trials Arena, 28 October 2026.It will be interesting when the report comes out whether Novo still makes as much money since they are forced to constantly lower their prices and thus their margins. If the report shows that they can still have a good margin, I believe it could be a small boost.
- ·3 t sittenGenmab/Novo. Genmab shows that a stock can go from total depth of despair to higher altitudes when the market suddenly gains confidence in the company's pipeline. The stock has risen massively after strong trial results. The question is then whether Novo can do the same. They certainly can, but it requires Novo to once again deliver strong results with new obesity and diabetes drugs, win some market share from Eli Lilly and get investors to believe in growth again. Therefore, Novo can easily make a strong comeback, but you should not necessarily expect the same explosive percentage increases as in Genmab. Not a buy/sell recommendation.Agree with what you are writing. For a long time, the Genmab share reacted exactly the way Novo does today - it fell on both good and bad news. Patience rewards itself and trust can quickly be regained. Pleased with Genmab's success and believe it will soon turn around for Novo too.
- ·4 t sittenMy thoughts. I believe in a positive report and a positive market reaction next week. At the last report we were approx 80 kr higher around 330-335. So it has already taken a beating. Dollar is strengthening, which is good for Novo and they are rapidly entering new markets. Last time, I had sold off nicely before the report. This time I have loaded up. 🆙Before the last earnings report, the share price was around 305. Inconceivable how little factual information there is here. Everything is drifting.
- ·4 t sittenGenmab on the way to overtake novo in market value? It is approaching well 3-400 billion kr? Fantastic news today for the people who are diagnosed with head and neck cancer. Simply fantastic !!!!!Novo on the other hand is about to get an obesity product approved in Dubai. The market is excited and responds with a minor drop of a couple of percent. Novo is doing eminently.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 337 | ||
| 135 | ||
| 134 | ||
| 269 | ||
| 537 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 5 015 221 | 5 015 221 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 5 015 221 | 5 015 221 | 0 | 0 |